Discontinuation of warfarin | P value | ||
---|---|---|---|
Without bridging | With bridging | ||
Biopsy, n | 49 | 19 | |
Patients, n | 46 | 18 | |
Age (years) | 72 (68, 76) | 73 (71, 76) | 0.406 |
PSA (ng/mL) | 8.8 (5.4, 13.6) | 10.5 (7.0, 14.9) | 0.333 |
Diabetes, n | 5 (10%) | 5 (26%) | 0.128 |
Hypertension, n | 23 (47%) | 7 (37%) | 0.588 |
Concurrent antithrombotic agents | 1.000 | ||
Warfarin alone, n | 34 (69%) | 13 (68%) | |
Warfarin + others, n | 15 (31%) | 6 (32%) | |
PT-INR (at a target level) | 1.55 (1.19, 1.92) | 1.89 (1.67, 2.32) | 0.026 |
CHAD2 score | 1 (1, 3) | 1 (0, 3) | 0.701 |